Drug intelligence / Profile preview

GAIA-102 + pembrolizumab

Development stage: Unknown
Lead developer: GAIA BioMedicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GAIA-102 + pembrolizumab is a combination therapy consisting of GAIA-102 (NK-cell-like cells) and pembrolizumab (an anti-PD-1 antibody). This combination is being investigated for its potential synergistic effects in treating various cancers, particularly non-small cell lung cancer (NSCLC) and microsatellite stable (MSS) advanced gastrointestinal cancers. GAIA-102 is a proprietary NK-cell-like therapy developed by GAIA BioMedicine Inc., while pembrolizumab is a well-established immune checkpoint inhibitor that blocks the PD-1 pathway to help the immune system fight cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GAIA-102 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAIA-102 + pembrolizumab.

Explore the full profile